Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Other Non-Current Liabilities: 2018-2025

  • Dr Reddys Laboratories' Other Non-Current Liabilities fell 18.75% to $39.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $39.0 million, marking a year-over-year decrease of 18.75%. This contributed to the annual value of $39.0 million for FY2025, which is 18.75% down from last year.
  • Dr Reddys Laboratories' Other Non-Current Liabilities amounted to $39.0 million in Q1 2025, which was down 18.75% from $48.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' Other Non-Current Liabilities' 5-year high stood at $48.0 million during Q1 2024, with a 5-year trough of $32.0 million in Q1 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $39.0 million (2025), whereas its average is $40.7 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 37.14% in 2024, then declined by 18.75% in 2025.
  • Quarterly analysis of 5 years shows Dr Reddys Laboratories' Other Non-Current Liabilities stood at $32.0 million in 2021, then remained steady at $32.0 million in 2022, then grew by 9.38% to $35.0 million in 2023, then skyrocketed by 37.14% to $48.0 million in 2024, then dropped by 18.75% to $39.0 million in 2025.
  • Its last three reported values are $39.0 million in Q1 2025, $48.0 million for Q1 2024, and $35.0 million during Q1 2023.